Octapharma Dessau GmbH – FDA 483, Nov 8, 2024
Octapharma Dessau GmbH received a Form 483 for deficiencies in their quality system, specifically regarding biological product deviation reporting, investigation records, batch production documentation, and quality control unit responsibilities. The inspection revealed issues with misaligned SOPs, lack of effectiveness checks for corrective actions, undocumented critical packaging steps, and inadequate qualification of visual inspection equipment. These findings indicate a need for improved procedural alignment and robust quality oversight to ensure product quality and compliance.
ID · febef994-75e8-4a6e-a475-701c2c78c4a2
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.